Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA–DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum

Arthritis and Rheumatology

Volumn 69, Issue 5, 2017, Pages 1090-1099

  Rothwell, Simon ^a   Cooper, Robert G ^b   Lundberg, Ingrid E ^c   Gregersen, Peter K ^d   Hanna, Michael G ^e   Machado, Pedro M ^e   Herbert, Megan K ^f,g   Pruijn, Ger J M ^g   Lilleker, James B ^a,h   Roberts, Mark ^h   Bowes, John ^a   Seldin, Michael F ⁱ   Vencovsky, Jiri ^j   Danko, Katalin ^k   Limaye, Vidya ^l   Selva O'Callaghan, Albert ^m   Platt, Hazel ^a   Molberg, Øyvind ⁿ   Benveniste, Olivier ^o   Radstake, Timothy R D J ^p   Doria, Andrea ^q   De Bleecker, Jan ^r   De Paepe, Boel ^r   Gieger, Christian ^s   Meitinger, Thomas ^s,t   Winkelmann, Juliane ^s,t   Amos, Christopher I ^u   Ollier, William E ^a   Padyukov, Leonid ^v   Lee, Annette T ^d   Lamb, Janine A ^a   Chinoy, Hector ^w   Denton, Christopher ^x   Gheorghe, Karina ^v   Hilton Jones, David ^y   Kiely, Patrick ^z   Mann, Herman ^aa   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^h SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CHARLES UNIVERSITY   (Czech Republic)

^k UNIVERSITY OF DEBRECEN   (Hungary)

^l ROYAL ADELAIDE HOSPITAL   (Australia)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ UNIVERSITY OF OSLO   (Norway)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^p UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^q UNIVERSITY OF PADOVA   (Italy)

^r GHENT UNIVERSITY HOSPITAL   (Belgium)

^s INSTITUTE OF EPIDEMIOLOGY   (Germany)

^t TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^u DARTMOUTH COLLEGE   (United States)

^v KAROLINSKA INSTITUTE   (Sweden)

^w MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^x ROYAL FREE HOSPITAL   (United Kingdom)

^y JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^z ST GEORGE S HOSPITAL   (United Kingdom)

^aa INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; AUTOANTIBODY; CCR5 PROTEIN, HUMAN;

ALLELE; AMINO ACID SEQUENCE; ANTIBODY DETECTION; ARTICLE; AUSTRALIA; AUTOIMMUNE DISEASE; BELGIUM; CAUCASIAN; CHROMOSOME 3P; CONTROLLED STUDY; CZECH REPUBLIC; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRAMESHIFT MUTATION; FRANCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION STUDY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GERMANY; HEREDITY; HLA SYSTEM; HUMAN; HUNGARY; INCLUSION BODY MYOSITIS; ITALY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NETHERLANDS; NORWAY; ONSET AGE; POLAND; POLYMYOSITIS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; SWEDEN; UNITED KINGDOM; UNITED STATES; YOUDEN INDEX; CHROMOSOME 3; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

AGE OF ONSET; AUTOANTIBODIES; CHROMOSOMES, HUMAN, PAIR 3; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HLA-DRB1 CHAINS; HUMANS; MYOSITIS, INCLUSION BODY; RECEPTORS, CCR5;

EID: 85013723160     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40045     Document Type: Article

References (42)

1. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408–18.
2. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397–407.
3. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620–31.
4. Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun 2015;16:470–80.
5. Rojana-udomsart A, James I, Castley A, Needham M, Scott A, Day T, et al. High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes. J Neuroimmunol 2012;250:77–82.
6. Sivakumar K, Cervenakova L, Dalakas MC, Leon-Monzon M, Isaacson SH, Nagle JW, et al. Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol 1995;38:267–9.
7. Needham M, Hooper A, James I, van Bockxmeer F, Corbett A, Day T, et al. Apolipoprotein ε alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Disord 2008;18:150–2.
8. Gang Q, Bettencourt C, Machado PM, Fox Z, Brady S, Healy E, et al. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging 2015;36:1766.e1–3.
9. Gang Q, Bettencourt C, Machado P, Hanna MG, Houlden H. Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet J Rare Dis 2014;9:88.
10. Weihl CC, Baloh RH, Lee Y, Chou TF, Pittman SK, Lopate G, et al. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord 2015;25:289–96.
11. Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis 2016;75:1558–66.
12. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705–13.
13. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis. MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010;20:142–7.
14. Rose MR. 188th ENMC International Workshop: inclusion body myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013;23:1044–55.
15. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012;44:1336–40.
16. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661–78.
17. International Multiple Sclerosis Genetics Consortium, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013;45:1353–60.
18. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011;43:1193–201.
19. Wichmann HE, Gieger C, Illig T, for the MONICA/KORA Study Group. KORA-gen: resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 2005;67 Suppl 1:S26–30.
20. 151Pro→Ala change in TNIP1 and to HLA-B*08. Ann Neurol 2012;72:927–35.
21. Li MX, Yeung JMY, Cherny SS, Sham PC. Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. Hum Genet 2012;131:747–56.
22. Machiela MJ, Chanock SJ. LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015;31:3555–7.
23. Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013;8:e64683.
24. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, et al. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2016;75:696–701.
25. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–5.
26. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, et al. Genetics and beyond: the transcriptome of human monocytes and disease susceptibility. PLoS One 2010;5:e10693.
27. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013;7:7.20.
28. Mastaglia FL, Needham M, Scott A, James I, Zilko P, Day T, et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 2009;19:763–5.
29. Scott AP, Laing NG, Mastaglia F, Dalakas M, Needham M, Allcock RJ. Investigation of NOTCH4 coding region polymorphisms in sporadic inclusion body myositis. J Neuroimmunol 2012;250:66–70.
30. Rojana-udomsart A, Mitrpant C, James I, Witt C, Needham M, Day T, et al. Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC class II region in sporadic inclusion body myositis. J Neuroimmunol 2013;254:174–7.
31. Lenz TL, Deutsch AJ, Han B, Hu X, Okada Y, Eyre S, et al. Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nat Genet 2015;47:1085–90.
32. Kim K, Bang SY, Lee HS, Okada Y, Han B, Saw WY, et al. The HLA-DRβ1 amino acid positions 11-13-26 explain the majority of SLE-MHC associations. Nat Commun 2014;5:5902.
33. Limaye VS, Lester S, Blumbergs P, Greenberg SA. Anti- C N1A antibodies in South Australian patients with inclusion body myositis. Muscle Nerve 2016;53:654–5.
34. Provost TT, Watson R. Anti-Ro(SS-A) HLA-DR3-positive women: the interrelationship between some ANA negative, SS, SCLE, and NLE mothers and SS/LE overlap female-patients. J Invest Dermatol 1993;100:S14–20.
35. Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J, et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet 2013;45:664–9.
36. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010;42:295–302.
37. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013;45:202–7.
38. Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet 2015;47:381–6.
39. Hinks A, Martin P, Flynn E, Eyre S, Packham J, Childhood Arthritis Prospective Study (CAPS), UKRAG Consortium, BSPAR Study Group, et al. Association of the CCR5 gene with juvenile idiopathic arthritis. Genes Immun 2010;11:584–9.
40. Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier JF, Figarella-Branger D. Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005;31:70–9.
41. De Paepe B, de Bleecker JL. β-chemokine receptor expression in idiopathic inflammatory myopathies. Muscle Nerve 2005;31:621–7.
42. Desmetz C, Lin YL, Mettling C, Portalès P, Noël D, Clot J, et al. Cell surface CCR5 density determines the intensity of T cell migration towards rheumatoid arthritis synoviocytes. Clin Immunol 2007;123:148–54.